Aulos
Aulos Bioscience develops an immune‑activating antibody therapeutic, imneskibart (AU‑007), that binds the interleukin‑2 region interacting with the CD25 receptor to shift IL‑2 activity toward immune activation and away from suppression. The company is advancing this investigational product in Phase 1/2 trials for patients with unresectable locally advanced or metastatic solid‑tumor cancers, including melanoma and renal cell carcinoma. Its focus is on delivering a novel IL‑2‑based therapy to cancer patients and the clinical research community.
Aulos is profiled on the APIs.io network. Tagged areas include Oncology, Biopharma, Antibody Therapeutics, IL-2 Therapeutics, and Clinical Trials.
Aulos’ developer surface includes documentation and 15 more developer resources.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Privacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Eligibility 1
Who may sign up and where, quoted from its own terms.
AI Preferences 1
Its stance on AI training, inference and agents, quoted from its own pages.
Data License 1
How its data and outputs may be reused, quoted from its own terms.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Documentation 2
Reference material describing how the API behaves
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 4
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 4
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.